Abstract
Background Lithium is the most effective treatment in bipolar disorder. Its use is limited by concerns about risk of chronic kidney disease (CKD). We aimed to develop a model to predict risk of CKD following lithium treatment initiation, by identifying individuals with a high-risk trajectory of renal function.
Methods We used United Kingdom Clinical Practice Research Datalink (CPRD) electronic heath records (EHRs) from 2000-2018. CPRD Aurum for prediction model development and CPRD Gold for external validation. We used elastic net to generate a prediction model from potential features. We performed discrimination and calibration assessments in an external validation data set.
We included all patients aged ≥16 with bipolar disorder prescribed lithium. To be included patients had to have ≥1 year of follow-up before lithium initiation, ≥3 estimated glomerular filtration rate (eGFR) measures after lithium initiation (to be able to determine a trajectory) and a normal (≥60 mL/min/1.73m2) eGFR at lithium initiation (baseline). In the Aurum development cohort 1609 fulfilled these criteria. The Gold external validation cohort included 934 patients.
We included 44 potential baseline features in the prediction model, including sociodemographic, mental and physical heath and drug treatment characteristics. We compared a full model with the 3-variable five-year kidney failure risk equation (KFRE) and a 3-variable elastic net model.
We used group-based trajectory modelling to identify latent trajectory groups for eGFR. We were interested in the group with deteriorating renal function (the high-risk group).
Findings The high-risk group included 191 (11.87%) of the Aurum cohort and 137 (14.67%) of the Gold cohort, of these 168 (87.96%) and 117 (85.40%) respectively developed CKD 3a or more severe during follow-up. The model, developed in Aurum, had a ROC area of 0.879 (95%CI 0.853-0.904) in the Gold external validation data set. At the empirical optimal cut-point defined in the development dataset, the model had a sensitivity of 0. 91 (95%CI 0.84-0.97) and a specificity of 0.74 (95% CI 0.67-0.82). However, a 3-variable elastic net model (including only age, sex and baseline eGFR) performed similarly well (ROC area 0.888; 95%CI 0.864-0.912), as did the KFRE (ROC area 0.870; 95%CI 0.841-0.898).
Conclusions Individuals at high-risk of a poor trajectory of renal function can be identified before initiation of lithium treatment by a simple equation including age, sex and baseline eGFR. We did not identify strong predicters of renal impairment specific to lithium treated patients.
Competing Interest Statement
IW received research funding from Bristol-Myers Squibb, Pfizer, and Janssen Pharmaceutica outside the submitted work. No other authors report competing interests.
Funding Statement
This study was supported by grant 211085/Z/18/Z from the Wellcome Trust (JFH), the University College London Hospitals National Institute for Health Research Biomedical Research Centre (JFH, DPJO, GL), NIHR North Thames Applied Research Collaboration (JFH, DPJO), grant 523-2010-1052 from the Swedish Research Council (CD)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Independent Scientific Advisory Committee of CPRD (protocol no. 18_316). Informed consent was waived because data are anonymised for research purposes. In line with ethical guidance subgroups containing fewer than 5 people are censored in the results section.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is avaiable via the Clinical Practice Research Datalink (https://www.cprd.com/) following appropriate ethical approval.
